- Company Details
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.Amount: $222,192.00
In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are propos ...STTRPhase I2016Department of Health and Human Services
DESCRIPTION (provided by applicant): Recent evidence suggests that the primary cause of Alzheimer's disease is the progressive accumulation of neurotpxic oligomeric assemblies of the Abeta 1-42 prote ...SBIRPhase I2005Department of Health and Human Services
DESCRIPTION (provided by applicant): The molecular and cellular details underlying Alzheimer's disease (AD) are being defined at an accelerating pace, leading to new therapeutic discovery efforts tha ...SBIRPhase I2005Department of Health and Human Services
Acumen Pharmaceuticals, Inc.
385 Oyster Point Blvd.
South San Francisco, CA, 94080
|# of Employees:||N/A|
|Socially and Economically Disadvantaged:||N|